Vejle Hospital
π©π°Denmark
- Country
- π©π°Denmark
- Ownership
- Private
- Established
- 1890-01-01
- Employees
- -
- Market Cap
- -
Neoadjuvant Treatment of Colon Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT01108107
- Locations
- π©π°
Dept. of Oncology, Hilleroed Hospital, Hilleroed, Denmark
π©π°Department of Oncology, Vejle Hospital, Vejle, Denmark
π©π°Department of Oncology, Herlev Hospital, Herlev, Denmark
First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2014-12-04
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT01038037
- Locations
- π©π°
Vejle Hospital, Vejle, Denmark
Norspan Versus Oxycontin as Postoperative Painkiller to Proximal Extracapsular Fractures of the Femur
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT00964808
- Locations
- π©π°
Orthopaedic Department, Vejle, Denmark
Watchful Waiting. An Observational Study of Patients With Rectal Cancer After Concomitant Radiation and Chemotherapy
Completed
- Conditions
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT00952926
- Locations
- π©π°
Vejle Hospital, Vejle, Denmark
Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type
Phase 2
Completed
- Conditions
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT00861120
- Locations
- π©π°
Herning Regional Hospital, Herning, Denmark
π©π°Vejle Hospital, Dept. of Oncology, Vejle, Denmark
π¦πΉAGO Austria, Innsbruck, Austria
Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00827684
- Locations
- π©π°
Vejle Hospital, Dept. of Oncology, Vejle, Denmark
π©π°Rigshospitalet, Department of Oncology, Copenhagen, Denmark
Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations
Phase 2
Completed
- Conditions
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2012-06-13
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT00792363
- Locations
- π©π°
Vejle Hospital, Dept. of Oncology, Vejle, Denmark
Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT00779454
- Locations
- π©π°
Vejle Hospital, Dept. of Oncology, Vejle, Denmark
Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2008-09-26
- Last Posted Date
- 2011-12-07
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00760370
- Locations
- π©π°
Odense University Hospital, Odense, Denmark
π©π°Vejle Hospital, Vejle, Denmark
Bevacizumab and Carboplatin for Patients With Ovarian Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2008-09-01
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 73
- Registration Number
- NCT00744718
- Locations
- π©π°
Vejle Hospital, Vejle, Denmark
Β© Copyright 2024. All Rights Reserved by MedPath